Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer

Phase 2

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: Irinotecan
Radiation: Neoadjuvant Radiotherapy

First Posted Date: 2020-06-02

Last Posted Date: 2020-06-02

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT04411537

Locations: 🇨🇳
Zhen Zhang, Shanghai, Shanghai, China

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Phase 3

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Traditional Chinese Medicine Formulation
Drug: Placebo Formulation

First Posted Date: 2020-05-27

Last Posted Date: 2020-06-01

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04403529

Locations: 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

Phase 2

Active, not recruiting

Conditions: TNBC - Triple-Negative Breast Cancer

First Posted Date: 2020-05-20

Last Posted Date: 2023-12-22

Lead Sponsor: Fudan University

Target Recruit Count: 139

Registration Number: NCT04395989

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer

Phase 2

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: Dendrobium Huoshanense Granules
Radiation: Pelvic Radiation
Drug: Capecitabine
Other: Placebo
Drug: Irinotecan

First Posted Date: 2020-05-19

Last Posted Date: 2020-05-19

Lead Sponsor: Fudan University

Target Recruit Count: 210

Registration Number: NCT04394598

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: capecitabine and trastuzumab
Drug: endocrine therapy and trastuzumab

First Posted Date: 2020-05-12

Last Posted Date: 2024-03-22

Lead Sponsor: Fudan University

Target Recruit Count: 356

Registration Number: NCT04383275

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Phase 2

Conditions: Sarcoma, Soft Tissue

Interventions: Drug: Sintilimab
Drug: Doxorubicin Hydrochloride
Drug: Ifosfamide

First Posted Date: 2020-04-22

Last Posted Date: 2020-07-14

Lead Sponsor: Fudan University

Target Recruit Count: 45

Registration Number: NCT04356872

Locations: 🇨🇳
Fudan University, Cancer Hospital, Shanghai, Shanghai, China

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer
Metastatic Cancer

Interventions: Drug: SHR7390
Drug: SHR3162
Drug: Pyrotinib
Drug: Everolimus
Drug: SHR1210
Drug: SHR2554
Drug: SHR6390
Drug: SHR3680
Drug: Famitinib
Drug: Capecitabine
Drug: Nab paclitaxel
Drug: SHR1701
Drug: SERD
Drug: AI
Drug: VEGFi

First Posted Date: 2020-04-21

Last Posted Date: 2022-07-26

Lead Sponsor: Fudan University

Target Recruit Count: 319

Registration Number: NCT04355858

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma

Not Applicable

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma
Metastasis
Stereotactic Body Radiation Therapy

Interventions: Radiation: SBRT

First Posted Date: 2020-04-17

Last Posted Date: 2020-04-17

Lead Sponsor: Fudan University

Target Recruit Count: 43

Registration Number: NCT04351282

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Effects of Fasting Strategies on Postoperative Recovery and Long-term Prognosis in Patients With Colorectal Cancer

Not Applicable

Conditions: Complication of Surgical Procedure
Colorectal Cancer
Fasting
Immune Suppression

Interventions: Behavioral: Fasting hours

First Posted Date: 2020-04-15

Last Posted Date: 2020-08-11

Lead Sponsor: Fudan University

Target Recruit Count: 2400

Registration Number: NCT04345978

Locations: 🇨🇳
Fudan University,ZhongShan Hospital, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer center, Shanghai, Shanghai, China
🇨🇳
Shanghai Changhai Hospital, Naval Medical University,, Shanghai, Shanghai, China

and more 4 locations

Intraoperative Infusion of Methylene Blue for Prevention of Postoperative Delirium and Cognitive Dysfunction in Elderly Patients Undergoing Major Elective Noncardiac Surgery

Not Applicable

Completed

Conditions: Postoperative Delirium
Postoperative Cognitive Dysfunction

Interventions: Drug: Placebo
Drug: Methylene Blue

First Posted Date: 2020-04-10

Last Posted Date: 2020-10-27

Lead Sponsor: Fudan University

Target Recruit Count: 248

Registration Number: NCT04341844

Locations: 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy